Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03252535Phase 2Completed

Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease

Role: collaborator

NCT06097780Phase 3Not Yet Recruiting

Efficacy and Safety of NestaCell® in Huntington's Disease

Role: collaborator

NCT02728115Phase 1Unknown

Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease

Role: collaborator

NCT04219241Phase 2Unknown

Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.

Role: collaborator

NCT04315987Phase 2Completed

NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia

Role: collaborator

All 5 trials loaded